BCRX BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About BioCryst Pharmaceuticals (NASDAQ: BCRX)
›
BioCryst Pharmaceuticals (NASDAQ: BCRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 435 employees.
The shares were at 7.320 USD on 19 November 2026, up 4.1% over 52 weeks. Its 52-week range is 6.230 USD to 11.22 USD: the price is 34.8% below the high and 17.5% above the low.
Its market capitalisation is 1.88B USD.
BioCryst Pharmaceuticals reports return on equity of -221.4%, an operating margin of 48.8% and revenue up 13.1% year over year.
Its debt exceeds its cash by 453.20M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 20.45 USD is 179.4% above the current price. The next earnings report is expected on 25 February 2027.